Lopes RD, et al. - Researchers attempted to study the effectiveness and safety of anticoagulants in adults with non-valvular atrial fibrillation and concomitant coronary/peripheral artery disease. From 01 Jan 2013 to 31 Sep 2015, non-valvular atrial fibrillation patients ≥65 years diagnosed with coronary/peripheral artery disease in the US Medicare population, newly initiating direct oral anticoagulants {DOACs} (apixaban, rivaroxaban, dabigatran) or warfarin were chosen. Findings revealed that all DOACs were linked with lower stroke/myocardial infarction/all-cause mortality rates compared to warfarin. However, differences were observed in rates of stroke/systemic embolism and major bleeding. This investigation gave important insights about oral anticoagulation therapy among non-valvular atrial fibrillation patients with coronary/peripheral artery disease and could help practitioners in the decision-making process when treating this high-risk group of patients.